Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease

Citations Over TimeTop 10% of 2008 papers

Abstract

SAR on HTS hits 1 and 2 led to the potent, Notch-1-sparing GSI 9, which lowered brain Abeta in Tg2576 mice at 100 mg/kg po. Converting the metabolically labile methyl groups in 9 to trifluoromethyl groups afforded the more stable analogue 10, which had improved in vivo potency. Further side chain modification afforded the potent Notch-1-sparing GSI begacestat (5), which was selected for development for the treatment of Alzheimer's disease.

Related Papers

• → A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain(1999)2,092 cited
• → Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1(2000)518 cited
• → Are Presenilins Intramembrane-Cleaving Proteases? Implications for the Molecular Mechanism of Alzheimer's Disease(1999)201 cited
• → Is γ-secretase a multienzyme complex for membrane protein degradation?(2002)11 cited
• → P4‐189: Changes in the clevage precision of presenilin/γ‐secretase regulate notch signaling intensity(2008)